NEW YORK, August 10, 2026, 13:12 EDT — U.S. markets open.
- UnitedHealth shares rose 1.1% to $411.53 in afternoon trading.
- Optum Health reported $2.486 billion in adjusted operating earnings for the first half, reaching 112% of its minimum full-year target, according to an initial estimate.
- Teamwork Financial Advisors owned 31,314 shares, representing around 1.2% of its reported portfolio.
Initial estimates indicate that Optum Health has achieved 112% of its 2026 adjusted operating-profit minimum. The company’s adjusted operating earnings totaled $2.486 billion in the first half, surpassing the $2.215 billion minimum target.
The reason this is important is that management anticipates minimal net unit profit beyond June. Chief Financial Officer Wayne DeVeydt projected a small profit for the third quarter, followed by an anticipated minor loss in the fourth quarter.
Shares are priced at $411.53, representing 20.8 times the midpoint of adjusted EPS guidance. The consensus price target from 27 MarketBeat analysts is $455.92, reflecting an increase of roughly 11%. The current valuation relies on sustainability through 2027.
UnitedHealth integrates its UnitedHealthcare insurance services with Optum’s operations, which include care, data, and pharmacy divisions. Optum Health serves as the care delivery segment.
Optum Health earnings are primarily generated in the first half
| $ billion, except margins | Q1 2026 | Q2 2026 | H1 2026 | FY 2026 minimum |
|---|---|---|---|---|
| Revenue | 24.109 | 23.472 | 47.581 | — |
| Reported operating profit | 1.141 | 1.190 | 2.331 | >2.275 |
| Adjusted operating profit | 1.312 | 1.174 | 2.486 | >2.215 |
| Adjusted operating margin | 5.4% | 5.0% | 5.2% | — |
Profit for the first half reached 102.5% of the stated floor and 112.2% of the adjusted minimum, based on initial estimates compared with minimum thresholds rather than specific projections.
Contraction remains despite the rebound. Optum Health revenue in the first half declined by 4% to $47.6 billion, while the number of consumers served decreased from 95 million to 93 million.
DeVeydt stated the results were “not a reflection of a trend bending.” JPMorgan Chase NYSE:JPM analyst Lisa Gill noted that investors were seeking a “path” to $20. Reuters
Q2 performance compared to main benchmarks
| Measure | Q2 2026 result | Benchmark | Difference |
|---|---|---|---|
| Revenue | $112.032 billion | $111.616 billion, Q2 2025 | +0.4% |
| Operating earnings | $7.991 billion | $5.150 billion, Q2 2025 | +55.2% |
| Optum operating earnings | $4.049 billion | $3.075 billion, Q2 2025 | +31.7% |
| Adjusted EPS | $6.38 | $4.90 analyst estimate | +30.2% |
| Medical care ratio | 86.70% | 88.47% analyst estimate | 177 basis points improvement |
Company results are not audited. Analyst estimates come from Reuters.
Indicators of operations are getting better. According to Optum CEO Patrick Conway, transition support led to around a 10% drop in hospitalizations in certain areas. Ambient AI adoption has reached 70% of providers on staff.
UnitedHealth’s cash flow provides flexibility for management. The company reported $11.1 billion in operating cash for the quarter and spent $4 billion on share repurchases by mid-July. Total buybacks for the year are projected to be a minimum of $5 billion.
Analyst price targets vary widely, with recent estimates ranging from $380 to $529. Among 27 analysts, the average target is $455.92.
Latest analyst ratings
| Date | Brokerage | Analyst | Recommendation | Current target |
|---|---|---|---|---|
| July 21 | JPMorgan Chase NYSE:JPM | Lisa Gill | Overweight; price target lifted | $516 |
| July 17 | Morgan Stanley NYSE:MS | Erin Wright | Overweight; price target lifted | $529 |
| July 17 | UBS Group NYSE:UBS | A.J. Rice | Buy; price target lifted | $490 |
| July 16 | Robert W. Baird | Michael Ha | Upgraded to Neutral | $453 |
| July 6 | HSBC Holdings NYSE:HSBC | Sidharth Sahoo | Hold; price target lifted | $380 |
These recommendations were issued before trading began on Monday and may be updated.
Peer tape on Monday showed mixed performance.
| Company | Midday price | Daily move | Trailing P/E |
|---|---|---|---|
| UnitedHealth Group NYSE:UNH | $411.53 | up 1.1% | 31.0x |
| Humana NYSE:HUM | $387.82 | rising 0.7% | 36.6x |
| Elevance Health NYSE:ELV | $397.69 | increasing 0.9% | 17.6x |
| Cigna Group NYSE:CI | $279.06 | down 1.2% | 11.5x |
| CVS Health NYSE:CVS | $95.37 | off 0.3% | 25.2x |
Data was captured around 12:57 EDT. P/E ratios shown are trailing and not adjusted.
Teamwork raised its stake by 1,854.7%, but the increase was modest in dollar terms. At the end of the quarter, its 31,314 shares were valued at $13.0 million, representing around 1.2% of Teamwork’s reported portfolio and 0.0035% of UnitedHealth’s market capitalisation.
On August 5, Conway sold 500 shares of UnitedHealth at $410 each, amounting to a $205,000 transaction. Following the sale, Conway directly holds 16,496.797 shares. The Form 4 filing did not provide a reason.
Risks: Favorable reserve development totaling $860 million was recorded in the quarter. Estimates for medical costs are subject to change. Management anticipates a small loss at Optum Health in the fourth quarter. UnitedHealth additionally cites Justice Department Medicare actions as part of its identified risks.
The immediate challenge is not simply reporting another profit beat. Optum Health needs to steady its revenue and membership and maintain its margins. Clear evidence of this is required before 2027.
Related articles: NYSE:UNH
